GENETIC TECHNOLOGIES ADR EACH REPR 30 SPONGENETIC TECHNOLOGIES ADR EACH REPR 30 SPONGENETIC TECHNOLOGIES ADR EACH REPR 30 SPON

GENETIC TECHNOLOGIES ADR EACH REPR 30 SPON

No trades
See on Supercharts
Next report date
Report period
H2 2024
EPS estimate
Revenue estimate
‪2.87 M‬USD
Market capitalization
‪9.88 M‬USD
−28.6515USD
‪−7.90 M‬USD
‪5.84 M‬USD
Beta (1Y)
0.84

About GENETIC TECHNOLOGIES ADR EACH REPR 30 SPON

CEO
Simon Morriss
Headquarters
Fitzroy
Employees (FY)
60
Founded
1987
FIGI
BBG00X9DNJB0
Genetic Technologies Ltd. operates as a molecular diagnostics company, which engages in the provision of molecular risk assessment tests for cancer. It operates through EasyDNA, AffinityDNA and GeneType/Corporate segments. The EasyDNA segment focuses on EasyDNA branded test sales and expenses. The AffinityDNA segment focuses on AffinityDNA branded test sales and expenses.The GeneType/Corporate segment includes the GeneType branded test sales and expenses, including corporate charges. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.